CREST TO THE EUROCLEAR BANK SYSTEM As previously announced, at the extraordinary general meeting of the Company held on 12 February 2021 (the EGM ) shareholders approved the Migration and authorised the Board to take all steps necessary to implement it. In accordance with the terms of the Migration of Participating Securities Act 2019 (the 2019 Act ) and this authority, the Company has consented to the Migration and has made the requisite notifications to the Irish Companies Registration Office and Euronext Dublin. Accordingly, all steps required to be taken by the Company under the 2019 Act and the Migration Guide to give effect to the Migration have now been completed.
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
DUBLIN, Ireland, and Boston MA, March 11, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that subscription rights relating to warrants to acquire 283,389 Ordinary Shares (the “Warrants”) have been exercised. In order to satisfy the exercise of the Warrants, the Company on 11 March 2021 issued 283,389 ordinary shares of £0.06 each (“Ordinary Shares”) from treasury.
The Warrants were issued in connection with the listing of the Company on the AIM Market of the London Stock Exchange in 2016. Each warrant entitles the warrant holder to exercise subscription rights to subscribe for Ordinary Shares at a subscription price of £1.44 per Ordinary Share.
Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities
DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Remuneration Committee has approved the grant of 3,431,350 share options (
Options ) to subscribe for ordinary shares in the Company (
Shares ) under the Employee Share Option Plan 2019 (the
Plan ) to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.
The Options have an exercise price of US$2.804 per Share ($14.02 per ADS equivalent) (